News
Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...
1h
Investor's Business Daily on MSNTop-Performing Stock: CVS Health Raises Outlook After Strong Earnings BeatCVS stock has an attractive yield and earnings expansion. That makes it worth a look for investors seeking growth and income.
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...
Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...
Vinay Prasad, an academic and fierce critic of the medical mainstream, has been chosen to be the next director of the FDA ...
Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results